FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer

D Kazandjian, GM Blumenthal, W Yuan, K He… - Clinical Cancer …, 2016 - AACR
Abstract On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for
the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors …
被引用次数：248 相关文章

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer

D Kazandjian, GM Blumenthal, W Yuan, K He… - Clinical Cancer …, 2016 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> On July 13, 2015, the FDA approved gefitinib
(Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic non–small cell …

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.

D Kazandjian, GM Blumenthal, W Yuan… - … Cancer Research: an …, 2016 - europepmc.org
On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the
treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors …

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer

D Kazandjian, GM Blumenthal… - … : an official journal …, 2016 - pubmed.ncbi.nlm.nih.gov
On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the
treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors …